Molecular pathogenesis of oral squamous carcinoma

Journal of Clinical Pathology - Molecular Pathology

Volumn 53, Issue 4, 2000, Pages 165-172

  Williams, H K ^a  

^a BIRMINGHAM DENTAL HOSPITAL   (United Kingdom)

Author keywords

Oncogenes; Oral squamous carcinoma; Tumour suppressor genes

Indexed keywords

CANCER DIAGNOSIS; CELL ADHESION; CELL PROLIFERATION; CELL SPREADING; HUMAN; MOUTH CARCINOMA; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

CARCINOMA, SQUAMOUS CELL; CELL ADHESION MOLECULES; GENES, TUMOR SUPPRESSOR; HUMANS; MOUTH NEOPLASMS; ONCOGENES;

EID: 0033866818     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.53.4.165     Document Type: Review

References (113)

1. 1 Parkin DM, Laara E, Muir CS. Estimates of the world wide frequency of eighteen major cancers in 1995. Int J Cancer 1993;54:594-606.
2. 2 Macfarlane G, Boyle P, Evstifeeva T. Rising trends of oral cancer mortality among men worldwide: the return of an old public health problem. Cancer Causes Control 1994;5: 259-65.
3. 3 Vokes EE, Weichselbaum RR, Lippman SM, et al. Head and neck cancer. N Engl J Med 1993;328:184-94.
4. 4 Jovanic A, Ignaz GH, Pieter J. Secondary respiratory and upper digestive tract cancer following oral squamous cell carcinoma. Eur J Cancer B Oral Oncol 1994;30B:225-9.
5. 5 Ankathil R, Mathew A, Joseph F. Is oral cancer susceptibility inherited? Eur J Cancer B Oral Oncol 1996;32B:63-7.
6. 6 Jeffries S, Eeles R, Goldgar D, et al. The role of genetic factors in predisposition to squamous cell cancer of the head and neck. Br J Cancer 1999;79:865-7.
7. 7 Cooper M, Jovanic A, Nauta J. Role of genetic factors in the aetiology of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1995;121:157-60.
8. 8 Foulkes WD, Brunet J-S, Kowalski LP. Family history is a risk factor for squamous cell carcinoma of the head and neck in Brazil: a case control study. Int J Cancer 1995;63:769-73.
9. 9 Bongers V, Braakhuis B, Tobi H. The relation between cancer incidence among relatives and the occurrence of multiple primary carcinomas following head and neck cancer. Cancer Epidemiol Biomarkers Prev 1996;518:595-8.
10. 10 Sidransky D. Molecular genetics of head and neck cancer. Curr Opin Oncol 1995;7:229-33.
11. 11 Todd R, Donoff RB, Wong DTW. The molecular biology of oral cancer: toward a tumour progression model. J Oral Maxillofac Surg 1997;55:613-23.
12. 12 Bockmuhl U, Wolf G, Schmidt S, et al. Genomic alteration associated with malignancy in head and neck cancer. Head Neck 1998;20:145-51.
13. 13 El-Nagger AK, Hurr K, Batsakis JG, et al. Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma. Cancer Res 1995;55:2656-9.
14. 14 Partridge M, Emilion G, Pateromichelakis S, et al. Location of candidate tumour suppressor gene loci at chromosomes 3p, 8p and 9p for oral squamous carcinomas. Int J Cancer 1999;84:318-25.
15. 15 Partridge M, Emilion G, Paternomichelakis S, et al. The prognostic significance of allelic imbalance at key chromosomal loci in oral cancer. Br J Cancer 1999;79:1821-7.
16. 16 Califano J, van der Reit P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancenzation. Cancer Res 1996;56:2488-92.
17. 17 Emilion G, Langdon JD, Speight P, et al. Frequent gene deletions in potentially malignant oral lesions. Br J Cancer 1996;73:809-13.
18. 18 Partridge M, Emilion G, Paternomichelakis S, et al. Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral cancer, cumulative loci and its relationship with progression to cancer. Eur J Cancer B Oral Oncol 1998;34: 75-83.
19. 19 Sherman JA, Partridge M. Expression of retinoic acid precurcors in normal, dysplastic and malignant oral epithelium. Br J Oral Maxillofac Surg 1997;35:260-6.
20. 20 Field JK. Oncogenes and tumour suppresser genes in squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol 1992;28:67-76.
21. 21 Papadimitrakopoulou V, Izzo J, Lippman SM, et al. Frequent inactivation of p16 INK 4a in oral premalignant lesions. Oncogene 1997;14:1799-803.
22. 22 Hunter T, Pines J. Cyclins and cancer II: cyclin d and cdk inhibitors come of age. Cell 1994;74:573-82.
23. 23 Pande P, Mathur MR, Shukla NK, et al. PRb and p16 protein alterations in human oral tumorigenesis. Eur J Cancer B Oral Oncol 1998;34:396-403.
24. 24 Murray AW. Creative blocks: cell-cycle check points and feedback controls. Nature 1992;359:599-604.
25. 25 Pines J. Cyclins, CDKs and cancer [review]. Semin Cancer Biol 1995;6:63-72.
26. 26 Kotelnikov VM, Coon JS, Mundle S, et al. Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis. Clin Cancer Res 1997;3:95-101.
27. 27 Kushner J, Bradley G, Young B, et al. Aberrant expression of cycle A and cyclin B1 proteins in oral cancer. J Oral Pathol Med 1999;28:77-81.
28. 28 Bishop JM. Molecular themes in oncogencsis. Cell 1991;64: 235-48.
29. 29 Wong DT, Weller PF, Galli SJ, et al. Human eosinophils express transforming growth factor alpha. J Exp Med 1990; 172:673-81.
30. 30 Todd R, Chou MY, Matossian K, et al. Cellular sources of transforming growth factor-alpha in human oral cancer. J Dent Res 1990;70:917-23.
31. 31 Derynck R. The physiology of transforming growth factor-alpha. Adv Cancer Res 1992;58:27-52.
32. 32 Todd R, Donoff BR, Gertz R, et al. TGF-α and EGF receptor mRNAs in human oral cancers. Carcinogenesis 1989;10: 1553-6.
33. 33 Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of head and neck cancer. Cancer Res 1993;53: 3579-84.
34. 34 Partridge M, Gullick WJ, Langdon JD, et al. Expression of epidermoid growth factor receptor in oral squamous cell carcinoma. Br J Oral Maxillofac Surg 1988;26:381-9.
35. 35 Scully C. Oncogenes, tumour suppressers and viruses in oral squamous carcinoma. J Oral Pathol Med 1993;22:337-47.
36. 36 Christensen ME, Therkildsen MH, Hanson BL, et al. Immunoreactive transforming growth factor-α and epidermal growth factor in oral squamous cell carcinomas. J Pathol 1993;169:323-8.
37. 37 Santine J, Formento JL, Frauncoual M, et al. Characterisation, quantification and potential clinical value of epidermal growth factor receptor in head and neck squamous carcinomas. Head Neck 1991;13:132-39.
38. 38 Kutton NAA, Govard Ivan, Bhak NM. Epidermal growth factor receptor (EGFR) in oral squamous cell carcinomas: overexpression, localization and therapeutic implications. Indian J Dent Res 1997;8:9-18.
39. 39 Cantley LC, Auger KR, Carpenter C, et al. Oncogenes and signal transaction. Cell 1991;64:281-302.
40. 40 McDonald JS, Jones H, Pavelic ZP, et al. Immunohistochemical detection of the H-ras, K-ras and N-ras oncogenes in squamous cell carcinoma of the head and neck. J Oral Pathol Med 1994;23:342-6.
41. 41 Wendell G, Yarborough MD, Shores C, et al. Ras mutations and expression in head and neck squamous cell carcinomas. Laryngoscope 1994;104:1337-47.
42. 42 Kiaris H, Spandidos DA, Jones AS, et al. Mutations, expression and genomic instability of the H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer 1991;63:70-4.
43. 43 Milasin J, Pujic N, Dedovic N, et al. High incidence of H-ras mutations in squamous cell carcinoma of lip vermillion. J Oral Pathol Med 1994;23:298-301.
44. 44 Saranath D, Change Se, Bhotie LT, et al. High frequency of mutations in codons 12 and 61 of H-ras proto-oncogene in squamous cell carcinomas of the head and neck. Br J Cancer 1991;63:573-8.
45. 45 Kuo MYP, Jeng JK, Chiang CP, et al. Mutations of Ki-ras oncogene codon 12 in betel quid chewing-related human squamous cell carcinoma in Taiwan. J Oral Pathol Med 1994;23:70-4.
46. 46 Field JK. The role of oncognes and tumour suppressor genes in the aetiology of oral, head and neck squamous cell carcinoma. J R Soc Med 1995;88:35P-9P.
47. 47 Spandidos DA, Lamonthe A, Field JK. Multiple transcriptional activation of cellular oncogenes in human head and neck solid tumours. Anticancer Res 1985;5:221-4.
48. 48 Hooper ML. The role of p53 and Rls-1 genes in cancer development and apoptosis. J Cell Sci 1994;13:13-17.
49. 49 McConkey DJ, Zhivotosvsky B, Orrenius S. Apoptosis -molecular mechanisms and biochemical implications. Mol Aspects Med 1996;17:1-110.
50. 50 Williams ME, Gaffey MJ, Weiss LM, et al. Chromosome 11q13 amplification in head and squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1993;119:1238-43.
51. 51 Callender T, El-Nagger AK, Lee MS, et al. PRAD-1 (CCND) cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer 1994;74: 152-8.
52. 52 Yoshida T, Miyagawa K, Odagiri H, et al. Genomic sequence of hst, a transforming gene encoding a protein homologous to fibroblast growth factor and the int-2 encoded protein. Proc Natl Acad Sci U S A 1987;84:7305-9.
53. 53 Myoken Y, Okamoto T, Sato JD, et al. Immunocytochemical localisation of fibroblast growth factor-1 (FGF-1) and FGF-2 in oral squamous carcinoma (SCC). J Oral Pathol Med 1994;23:451-6.
54. 54 Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235:442-7.
55. 55 Lese CM, Rossie KM, Appel BN, et al. Visualisation of int-2 and HST1 amplification in oral squamous cell carcinomas. Genes Chromosomes Cancer 1985;12:288-95.
56. 56 Somers KD, Cartwright SL, Schechter GL. Amplification of the int-2 gene in human head neck squamous cell carcinomas. Oncogene 1990;5:915-20.
57. 57 Lee WH. Tumour suppressor genes - the hope [editorial]. FASEB J 1993;7:819.
58. 58 Yokota J, Sugimura T. Multiple steps in carcinogenesis involving alterations of multiple tumour suppress genes. FASEB J 1993;7:920-5.
59. 59 Vogelstein B, Kinzier KW. The multistep nature of cancer. Trends Genet 1993;9:138-41.
60. 60 Harper JW, Adamy GR, Wei N, et al. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
61. 61 El-Deiry WS, Tokino T, Velculesco VE, et al. WAF1, a potential mediator of p53 tumour suppression. Cell 1993;75:817-25.
62. 62 Datto MB, Li Y, Panus JF, et al. Transforming growth factor induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci U S A 1995;92:5545-9.
63. 63 Thomas R, Kaplan L, Reich N, et al. Characterization of human p53 antigens employing primate specific monoclonal antibodies. Virology 1983;131:502-17.
64. 64 Iggo R, Gatter K, Bartek J, et al. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-9.
65. 65 Hollstein M, Sidransky D, Volgelstein B, et al. p53 mutations in human cancers. Science 1991;253:49-53.
66. 66 Schantz SP. Basic science advances in head and neck oncology; the past decade. Semin Surg Oncol 1995;11:272-9.
67. 67 Langdon JD, Partidge M. Expression of the tumour suppressor gene p53 in oral cancer. Br J Oral Maxillofac Surg 1992;30:214-20.
68. 68 Brennan A, Boyle JO, Koch WM. Association between cigarette smoking and mutation of the p53 gene in squamous cell carcinoma of the head and neck. N Engl J Med 1995:332:712-17.
69. 69 Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 Tumour supressor gene: clues to cancer aetiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
70. 70 Lianes P, Orlow I, Zhang ZF, et al. Altered patterns of mdm2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 1994;86:1325-30.
71. 71 Heinzel PA, Balaram P, Hill B. Mutations and polymorphisms in the p53, p21 and p16 genes in oral carcinomas of Indian betel quid chewers. Int J Cancer 1996;68:420-3.
72. 72 Agarwal S, Mathur, Shukla NK, et al. Expression of cyclin dependent kinase inhibitor p21 waf1/cip1 in premalignant and malignant oral lesions: relationship with p53 status. Eur J Cancer B Oral Oncol 1998;34:353-60.
73. 73 Ng IOL, Lam KY, Ng M, et al. Expression of p21 waf1 in oral squamous cell carcinomas - correlation with p53 and mdm2 and cellular proliferation index. Eur J Cancer B Oral Oncol 1999;35:63-9.
74. 74 Shiohara M, El-Deiry WS, Wada N, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84:3781-4.
75. 75 Deng G, Chen L-C, Schott DR, et al. Loss of heterogygosity and p53 gene mutations in breast cancer. Cancer Res 1994; 54:499-505.
76. 76 Brooks JD, Bova GS, Ewing CM, et al. An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 1996;56:3814-22.
77. 77 Brachmann RK, Vidal M, Boeke JD. Dominant-negative mutations in yeast hit cancer hot spots. Proc Natl Acad Sci U S A 1996;93:4091-5.
78. 78 Varley JM, Brammar WJ, Lane DP, et al. Loss of chromosome 17p 13 sequences and mutation of p53 in human breast carcinomas. Oncogene 1991;6:413-21.
79. 79 Ahomadegbe JC, Barrois M, Fogel S, et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumours and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995;10:1217-27.
80. 80 Xu L, Chen Y-T, Huvos AG, et al. Overexpression of p53 in squamous cell carcinoma of head and neck without apparent gene mutations. Diagn Mol Pathol 1994;3:83-92
81. 81 Partridge M, Kiguwa S, Emilion G, et al. New insights into p53 protein stabilisation in oral squamous cell carcinoma. Eur J Cancer B Oral Oncol 1999;35-45-55.
82. 82 Midgeley CA, Lane DP. p53 protein stability in tumour cells is not determined by mutation but is dependent on mdm2 binding. Oncogene 1997;15:1179-89.
83. 83 Haupt Y, Maya R, Kazaz A, et al. Mdm2 provides the rapid degradation of p53. Nature 1997;387:296-9.
84. 84 Lane DP, Hall PA. MDM2 - arbiter of p53's destruction. Trends Biol Sci 1997;22:372-4.
85. 85 Brachman DG, Graves D, Vokes E, et al. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res 1992;52:4832-6.
86. 86 Min B-M, Baek JH, Shin KH, et al. Inactivation of the p53 gene by either mutation or HPV infection is extremely frequent in human oral squamous carcinoma cell lines. Eur J Cancer B Oral Oncol 1994;30B:338-45.
87. 87 Todd R, McBride J, Tsuji T, et al. Deleted in oral cancer-1 (doc-1) a novel oral tumour suppressor gene. FASEB J 1995;9:1362-70.
88. 88 Rustgi AK, Dyson N, Hill D, et al. The c-myc oncoprotein forms a complex with the product of the retinoblastoma gene. Cold Spring Harbor Symp Quant Biol 1991;56:163-7.
89. 89 Largey JS, Meltzer SJ, Sauk JJ, et al. Loss of heterozygosity involving the APC gene in squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1994;77:260-3.
90. 90 Huang JS, Chiang CP, Kok S-H. Loss of heterozygosity of APC and MCC genes in oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 1997;26:322-6.
91. 91 Behrens J, Vakaet L, Frii R, et al. Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/βcatenin complex in cells transformed with a temperature-sensitive V-SRC gene. J Cell Biol 1993;120:757-66.
92. 92 Bagutti C, Speight PM, Watt FM. Comparison of integrin, cadherin and catenin expressions in squamous cell cancinomas in the oral cavity. J Pathol 1998;186:8-16.
93. 93 Williams HK, Sanderes DSA, Jankowski JAZ, et al. Expression of cadherins and catenins in oral epithelial dysplasia and squamous cell carcinoma. J Oral Pathol Med 1998;27: 308-17.
94. 94 Becker KF, Atkinson MJ, Reich U, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994;54:3845-52.
95. 95 Behrens J, von Knes JP, Kuhl M, et al. Functional interaction of β-catenin with the transcription factor LEF-1. Nature 1996;382:638-42.
96. 96 Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signalling in colon cancer by mutations in β-catenin or APC. Science 1997;275:1787-90.
97. 97 Korineck V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC /-colon carcinoma. Science 1997;275:1784-7.
98. 98 Li-Kuo S, Vogelstein B, Kinzler KW. Association of the APC tumour suppressor protein with catenins. Science 1993;262: 1734-7.
99. 99 Smith MEF, Pagnatelli M. The molecular histology of neoplasia: the role of the cadherin/catenin complex. Histopathology 1997;31:107-11.
100. 100 Garzino-Demo P, Carrozo M, Trusolino L. Altered expression of alpha 6 integrin sub unit in oral squamous cell carcinoma and oral potentially malignant lesions. Eur J Cancer B Oral Oncol 1998;34:204-10.
101. 101 Shinohara M, Nakamura S, Sasaki M. Expression of integrins in squamous cell carcinoma of the oral cavity. Correlations with tumour invasion and metastasis. Am J Clin Pathol 1999;111:75-88.
102. 102 Thomas GJ, Jones J, Speight PM. Integrins and oral cancer. Eur J Cancer B Oral Oncol 1997;33:381-8.
103. 103 Jones J, Watt FM, Speight PM. Changes in expression of alpha V integrins in oral squamous cell carcinomas. J Oral Pathol Med 1997;26:63-8.
104. 104 Boyd D. Invasion and metastasis. Cancer Metastasis Rev 1996;15:77-89.
105. 105 Tryggvason K, Hoyhtya M, Sale T. Proteolytic degradation of extra cellular matrix in tumour invasion. Biochim Biophys Acta 1987;907:191-217.
106. 106 Flaitz CM, Hicks MJ. Molecular piracy: the viral link to carcinogenesis. Eur J Cancer B Oral Oncol 1998;34:448-53.
107. 107 Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993;341:1251-4.
108. 108 Bentler B, van Huffel C. Unravelling function of the TNF ligand and receptor families. Science 1994;264:667-8.
109. 109 Nagata S, Golstein P. The fas death factor. Science 1995;267:1449-56.
110. 110 Loro LL, Vintermyr OK, Johannessen AC, et al. Suppression of Fas receptor and negative correlation of Fas ligand with differentation and apoptosis in oral squamous cell carcinoma. J Oral Pathol Med 1999;28:82-7.
111. 111 Jordan RCK, Catzavelos GC, Barrett AW, et al. Differential expression of bcl-2 and bax in squamous cell carcinoma of the oral cavity. Eur J Cancer B Oral Oncol 1996;32B:394-400.
112. 112 Ravi D, Ramadas K, Matthew BS, et al. De novo programmed cell death in oral cancer. Histopathology 1999; 34:241-9.
113. 113 Partridge M, Emilion G, Falworth M, et al. Patient-specific mutation databases for oral cancer. Int J Cancer 1999;84: 284-92.